ARA-290

ARA-290 (Cibinetide) is a synthetic peptide derived from a non-hematopoietic region of erythropoietin (EPO) and engineered to selectively engage tissue-protective receptor signaling pathways. In laboratory and controlled clinical research, ARA-290 is studied for its interaction with the EPOR-CD131 receptor complex, commonly described as the innate repair receptor (IRR). Unlike full-length EPO, ARA-290 is investigated for pathway-selective activity that does not center on erythropoiesis, allowing focused evaluation of cytoprotective and anti-inflammatory signaling under controlled experimental conditions.

In vitro systems and structured clinical investigations evaluate endpoints including inflammatory cytokine modulation, NF-κB pathway activity, endothelial activation markers, immune cell signaling profiles, and cellular survival pathway indicators relative to controls. Additional research explores vascular biology endpoints such as endothelial progenitor behavior, tissue remodeling markers, and peripheral nerve structure and function parameters in defined experimental frameworks.